Abstract The US Food and Drug Administration (FDA) Adverse Event Reporting System
(FAERS, formerly AERS) is a database that contains information on adverse event and …

Amyotrophic lateral sclerosis (ALS) is characterised by the progressive degeneration of
upper and lower motor neurons. Besides motor neuron degeneration, ALS is associated …

Statins inhibit 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase, the rate-
limiting enzyme in cholesterol biosynthesis, which converts HMG-CoA to mevalonate …

Metabolic changes incorporating fluctuations in weight, insulin resistance, and cholesterol
concentrations have been identified in several neurodegenerative disorders. Whether these …

Adverse drug events (ADEs), including drug interactions, have a tremendous impact on
patient health and generate substantial health care costs. A “big data” approach to …

Objectives This article summarizes past and current data mining activities at the United
States Food and Drug Administration (FDA). Target audience We address data miners in all …

Background: Recently hyperlipidemia was reported to be related to a significantly better
outcome in amyotrophic lateral sclerosis (ALS). To investigate this, we evaluated the status …

Sporadic amyotrophic lateral sclerosis (ALS) is believed to be a complex disease in which
multiple exogenous and genetic factors interact to cause motor neuron degeneration …

Statins, cholesterol lowering drugs, have been demonstrated to exert beneficial effects in
other conditions such as primary and progressing neurodegenerative diseases beyond their …

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that results from the
death of upper and lower motor neurons. Due to a lack of effective treatment, it is imperative …